… and combined therapy with cetuximab. Limitations are the low … Management of cutaneous
toxicities of EGFR inhibitors is … skin toxicity of higher grades, with EGFR inhibitor cetuximab as …

… head and neck and colorectal cancer settings [30–43]. The … terms EGFR inhibitors, cetuximab,
skin toxicity, skin rash, and/or … to identify aspects of skin toxicity for which the treatment was …

… Radiotherapy plus cetuximab is an effective combination therapy for locally advanced
head … cell carcinoma. The aim of our study was to determine the frequency of skin toxicity in …

… Cutaneous toxicity in cetuximab-treated patients is summarized in Table 3. We report the
acne-like rash to be the most frequent cutaneous side effect of cetuximab therapy experienced …

… Purpose: The aim of this study was to investigate the efficacy of the combination of
irinotecan/cetuximab and to plan related skin toxicity management with an oncologic/dermatologic …

… of dermatological toxicity induced by cetuximab, compared … of each manifestation of cutaneous
toxicity may decrease the … the severity of skin toxicity associated with cetuximab, despite …

… 3 weeks until disease progression or unacceptable toxicity. Response was evaluated with
… had a chance to develop cetuximab-related skin toxicities were included into this analysis. …

… cell skin cancers [12]. As single agents, EGFR inhibitor monoclonal antibodies cetuximab
and … in patients with metastatic cutaneous squamous-cell carcinoma, but durable responses …

… The most common ADR was cutaneous toxicity. Severe radiation dermatitis or mucositis
has not been observed in cutaneous SCC patients with combined cetuximab radiotherapy in …

… of response to cetuximab. We hypothesized that early skin toxicity is a predictor of response
and better outcomes in patients with advanced colorectal carcinoma. We retrospectively …